RT Journal Article
SR Electronic
T1 Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1457
OP 1460
DO 10.2967/jnumed.120.258434
VO 62
IS 10
A1 Suh, Minseok
A1 Im, Hyung-Jun
A1 Ryoo, Hyun Gee
A1 Kang, Keon Wook
A1 Jeong, Jae Min
A1 Prakash, Sneha
A1 Ballal, Sanjana
A1 Yadav, Madhav P.
A1 Bal, Chandrasekhar
A1 Jeong, Chang Wook
A1 Kwak, Cheol
A1 Cheon, Gi Jeong
YR 2021
UL http://jnm.snmjournals.org/content/62/10/1457.abstract
AB 68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.